Clinical Trials Commence for First Adult TB Vaccine Derived from Human Source
Written by Arushi Sharma
A new chapter in tuberculosis (TB) prevention has begun with the commencement of clinical trials for MTBVAC, the first adult TB vaccine developed from a human source.
Bharat Biotech International Limited, in partnership with Biofabri, has initiated a series of clinical trials targeting adults in the country to assess the safety, immunogenicity, and efficacy of MTBVAC, marking a significant milestone in tuberculosis (TB) vaccine development.
MTBVAC stands as the first vaccine against TB derived from a human source, representing a promising avenue in the fight against this debilitating disease.
A spokesperson from Bharat Biotech highlighted that MTBVAC serves a dual purpose: to potentially supersede the BCG vaccine as a more effective and long-lasting immunization option for newborns, and to offer protection against TB disease in adults and adolescents—a demographic currently lacking access to an effective vaccine.
TB, a contagious respiratory disease, exacts a heavy toll globally, claiming over 1.6 million lives and infecting more than 10 million individuals each year. The initiation of clinical trials for MTBVAC underscores the urgency to address this pressing public health challenge and offers hope for improved prevention and control measures.
Acknowledging the significance of this development, Prof. Mandal expressed gratitude for the funding support received from the Science and Engineering Research Board (SERB) and the Department of Science and Technology (DST) to advance research efforts in the field of TB vaccination. This collaborative endeavor underscores the importance of interdisciplinary cooperation in tackling complex health issues.
The commencement of clinical trials marks a critical step forward in the quest for an effective TB vaccine tailored for adult populations. With millions worldwide bearing the burden of TB-related morbidity and mortality, the pursuit of innovative vaccine solutions holds immense promise in curbing the spread of this infectious disease and saving lives.
As researchers and clinicians continue to navigate the complexities of TB prevention and treatment, the ongoing trials of MTBVAC represent a beacon of hope, offering a potential breakthrough in the global fight against tuberculosis.